Curaleaf Raises Hostile Bid to US$5.00/Share; Aurora Extends Deadline to Dec 4
ACB sits 75% above its 52-week low of $2.56 on elevated volume (3.4× avg).
Summary
Curaleaf announced a revised hostile bid of US$5.00 per share (up from US$4.00), and Aurora confirmed the bid deadline has been extended to December 4, 2026 while its Special Committee reviews the formal offer.
Updates
· SEC SC14D9F/A — Aurora filed Amendment No. 3 to its Schedule 14D-9F, reiterating its recommendation that shareholders take no action pending review of Curaleaf's revised bid.
Key Events · M&A and Partnerships · ACB
-
Revised Hostile Bid Announced
Curaleaf stated its intention to file a Notice of Variation and Change to revise its hostile bid to US$5.00 per Aurora share, consisting of 0.4013 Curaleaf subordinate voting shares plus US$1.00 in cash — up from the original US$4.00 per share offer.
-
Bid Deadline Extended to December 4
Curaleaf agreed to extend the expiry time for the Hostile Bid to 11:59pm Mountain Time on December 4, 2026, giving Aurora shareholders additional time to consider their options.
-
Pro Forma Financials to Be Provided
In response to Aurora's application to the Alberta Securities Commission, Curaleaf agreed to amend its bid circular to include required pro forma financial statements showing the combined company's financial condition.
-
Special Committee Review Pending
Aurora's Special Committee of independent directors will review the formal revised offer once received and issue a recommendation within 15 days, in accordance with securities laws. Shareholders are advised to take no action until then.
Analysis · ACB · Life Sciences
Curaleaf has signaled a revised hostile takeover offer of US$5.00 per Aurora share — a 25% increase over its original US$4.00 bid — consisting of 0.4013 Curaleaf subordinate voting shares plus US$1.00 in cash. Aurora's Special Committee has not yet received the formal Notice of Variation and Change, so no recommendation has been made. The filing also confirms that Aurora's regulatory pressure on Curaleaf worked: Curaleaf agreed to include pro forma financial statements and extend the bid deadline to December 4, 2026, giving shareholders more time and better information to evaluate the offer. This is a material escalation in the ongoing hostile takeover battle.
How filings like this one have moved
In the 30 days to Oct 7, 2026, 36.1% of the 1056 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.2M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.